# Definitive Contract #75F40126C00093

Definitive Contract for AI-Driven Pharmaceutical Process Platform

**Buyer:** Food and Drug Administration

**Award Amount:** $456,721.00
**Ceiling:** $456,721.00

**Awarded:** September 30, 2026
**Period of Performance:** Sep 30, 2026 - Sep 29, 2028

**Identifier:** 75F40126C00093
**NAICS:** 541714

This definitive contract has been awarded to the University of Massachusetts Lowell, a prominent academic research institution known for its cutting-edge technology development. The contract entails research and development services to design, develop, validate, and deliver an innovative AI-assisted digital twin platform specifically for pharmaceutical lyophilization process development and scale-up. Lyophilization plays a critical role in drug preservation, and this platform is expected to significantly improve manufacturing efficiency and scalability in the pharmaceutical sector. The scope covers the entire lifecycle of the platform from initial design and validation through final delivery, tailored to meet pharmaceutical industry needs. The contract was competitively awarded, enabling the agency to utilize advanced AI technology from a leading research institution. Work will be performed in Silver Spring, Maryland, over a multi-year period to ensure thorough development and successful deployment of the platform.

### Description

TO PROVIDE RESEARCH AND DEVELOPMENT SERVICES TO DESIGN, DEVELOP, VALIDATE, AND DELIVER AN AI-ASSISTED DIGITAL TWIN PLATFORM FOR PHARMACEUTICAL LYOPHILIZATION PROCESS DEVELOPMENT AND SCALE-UP.

[View original record](https://www.usaspending.gov/award/CONT_AWD_75F40126C00093_7524_-NONE-_-NONE-)